Evidence map›Paper›PMID 26657175›Full record

ArticleThe international journal of neuropsychopharmacology2016

Relationship of Alexithymia Ratings to Dopamine D2-type Receptors in Anterior Cingulate and Insula of Healthy Control Subjects but Not Methamphetamine-Dependent Individuals.

Kyoji Okita, Dara G Ghahremani, Doris E Payer, Chelsea L Robertson, Mark A Mandelkern, Edythe D London

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The international journal of neuropsychopharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Neural underpinnings of maladaptive decision-making in addictions.Pharmacology, biochemistry, and behavior · 2018
    Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Kyoji OkitaDepartment of Psychiatry and Biobehavioral Sciences (Drs Okita, Ghahremani, and London), Department of Molecular and Medical Pharmacology (Drs Robertson and London), and Brain Research Institute (Dr London), University of California Los Angeles, Los Angeles, CA; Addiction Imaging Research Group, Centre for Addiction and Mental Health, Toronto, Ontario, Canada (Dr Payer); Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada (Dr Payer); Department of Research, VA Greater Los Angeles Healthcare System, Los Angeles, CA (Drs Okita, Robertson, Mandelkern, and London); Department of Physics, University of California Irvine, Irvine, CA (Dr Mandelkern).
Dara G GhahremaniDepartment of Psychiatry and Biobehavioral Sciences (Drs Okita, Ghahremani, and London), Department of Molecular and Medical Pharmacology (Drs Robertson and London), and Brain Research Institute (Dr London), University of California Los Angeles, Los Angeles, CA; Addiction Imaging Research Group, Centre for Addiction and Mental Health, Toronto, Ontario, Canada (Dr Payer); Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada (Dr Payer); Department of Research, VA Greater Los Angeles Healthcare System, Los Angeles, CA (Drs Okita, Robertson, Mandelkern, and London); Department of Physics, University of California Irvine, Irvine, CA (Dr Mandelkern).
Doris E PayerDepartment of Psychiatry and Biobehavioral Sciences (Drs Okita, Ghahremani, and London), Department of Molecular and Medical Pharmacology (Drs Robertson and London), and Brain Research Institute (Dr London), University of California Los Angeles, Los Angeles, CA; Addiction Imaging Research Group, Centre for Addiction and Mental Health, Toronto, Ontario, Canada (Dr Payer); Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada (Dr Payer); Department of Research, VA Greater Los Angeles Healthcare System, Los Angeles, CA (Drs Okita, Robertson, Mandelkern, and London); Department of Physics, University of California Irvine, Irvine, CA (Dr Mandelkern).
Chelsea L RobertsonDepartment of Psychiatry and Biobehavioral Sciences (Drs Okita, Ghahremani, and London), Department of Molecular and Medical Pharmacology (Drs Robertson and London), and Brain Research Institute (Dr London), University of California Los Angeles, Los Angeles, CA; Addiction Imaging Research Group, Centre for Addiction and Mental Health, Toronto, Ontario, Canada (Dr Payer); Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada (Dr Payer); Department of Research, VA Greater Los Angeles Healthcare System, Los Angeles, CA (Drs Okita, Robertson, Mandelkern, and London); Department of Physics, University of California Irvine, Irvine, CA (Dr Mandelkern).
Mark A MandelkernDepartment of Psychiatry and Biobehavioral Sciences (Drs Okita, Ghahremani, and London), Department of Molecular and Medical Pharmacology (Drs Robertson and London), and Brain Research Institute (Dr London), University of California Los Angeles, Los Angeles, CA; Addiction Imaging Research Group, Centre for Addiction and Mental Health, Toronto, Ontario, Canada (Dr Payer); Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada (Dr Payer); Department of Research, VA Greater Los Angeles Healthcare System, Los Angeles, CA (Drs Okita, Robertson, Mandelkern, and London); Department of Physics, University of California Irvine, Irvine, CA (Dr Mandelkern).
Edythe D LondonDepartment of Psychiatry and Biobehavioral Sciences (Drs Okita, Ghahremani, and London), Department of Molecular and Medical Pharmacology (Drs Robertson and London), and Brain Research Institute (Dr London), University of California Los Angeles, Los Angeles, CA; Addiction Imaging Research Group, Centre for Addiction and Mental Health, Toronto, Ontario, Canada (Dr Payer); Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada (Dr Payer); Department of Research, VA Greater Los Angeles Healthcare System, Los Angeles, CA (Drs Okita, Robertson, Mandelkern, and London); Department of Physics, University of California Irvine, Irvine, CA (Dr Mandelkern). elondon@mednet.ucla.edu.
University of California, Los Angeles · USUniversity of Toronto · CACentre for Addiction and Mental Health · CA

Funding

ZDV &3TC NEVIRAPINE COMBINATION THERAPY IN HIV 1 INFECTED INFANTS &M01RR000865 · NCRR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WASHINGTON, ARNOLD E. · 1985 to 2011
$43.4M
UCLA Training Program in Translational Neuroscience of Drug Abuse (TNDA)T32DA024635 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LARA A. RAY, Kate M Wassum · 2008 to 2026
$6.2M
NEUROCHEMISTRY OF MODAFINIL-MA INTERACTION IN RAT BRAINP20DA022539 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LONDON, EDYTHE DANICK · 2006 to 2009
$2.9M
Neural Systems, Inhibitory Control, and Methamphetamine DependenceR01DA020726 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LONDON, EDYTHE DANICK · 2005 to 2008
$2.0M
Early Methamphetamine Abstinence: fMRI and CognitionR01DA015179 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LONDON, EDYTHE D · 2003 to 2005
$1.4M
NCRR NIH HHS M01 RR000865NIDA NIH HHS P20 DA022539NIDA NIH HHS R01 DA015179NIDA NIH HHS R01 DA020726NIDA NIH HHS T32 DA024635
6 · The paper itself

Abstract

backgroundIndividuals with substance-use disorders exhibit emotional problems, including deficits in emotion recognition and processing, and this class of disorders also has been linked to deficits in dopaminergic markers in the brain. Because associations between these phenomena have not been explored, we compared a group of recently abstinent methamphetamine-dependent individuals (n=23) with a healthy-control group (n=17) on dopamine D2-type receptor availability, measured using positron emission tomography with [(18)F]fallypride.

methodsThe anterior cingulate and anterior insular cortices were selected as the brain regions of interest, because they receive dopaminergic innervation and are thought to be involved in emotion awareness and processing. The Toronto Alexithymia Scale, which includes items that assess difficulty in identifying and describing feelings as well as externally oriented thinking, was administered, and the scores were tested for association with D2-type receptor availability.

resultsRelative to controls, methamphetamine-dependent individuals showed higher alexithymia scores, reporting difficulty in identifying feelings. The groups did not differ in D2-type receptor availability in the anterior cingulate or anterior insular cortices, but a significant interaction between group and D2-type receptor availability in both regions, on self-report score, reflected significant positive correlations in the control group (higher receptor availability linked to higher alexithymia) but nonsignificant, negative correlations (lower receptor availability linked to higher alexithymia) in methamphetamine-dependent subjects.

conclusionsThe results suggest that neurotransmission through D2-type receptors in the anterior cingulate and anterior insular cortices influences capacity of emotion processing in healthy people but that this association is absent in individuals with methamphetamine dependence.

Indexed as

AdolescentAdultAffective SymptomsAmphetamine-Related DisordersBenzamidesCase-Control StudiesCentral Nervous System StimulantsCerebral CortexEmotionsFemaleGyrus CinguliHumansMagnetic Resonance ImagingMaleMethamphetamineMiddle AgedBenzamidesCentral Nervous System StimulantsDRD2 protein, humanMethamphetamineN-((1-allyl-2-pyrrolidinyl)methyl)-5-(3-fluoropropyl)-2,3-dimethoxybenzamidePyrrolidinesRadiopharmaceuticalsReceptors, Dopamine D2alexithymiadopamineemotion processingMethamphetamine dependencePET

Identifiers

PMID26657175
PMCPMC4886668
OpenAlexW2289260957

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.